What this library is, and is not
These are third-party films hosted on YouTube. We did not make them, we do not control them, and their contents are the speakers' views rather than ours — including where a speaker is more enthusiastic, or more critical, than we would be. Nothing here is medical advice, none of it is a claim about any product sold on this site, and the material we list is supplied for laboratory research use only. Where a film discusses use in people, that is a description of what its speaker said, not guidance to follow.
Nothing loads from YouTube until you press play. Thumbnails are served from our own server, so opening this page tells Google nothing about you — see the privacy notice.
Must watch
Start here.
PlayPowerfulJREJoe Rogan Experience #2469 — Brigham BuhlerBrigham Buhler, founder of Ways2WellThe most recent of the Ways2Well conversations. Covers the healthcare system, the regulatory position around peptides and hormones, and where Buhler argues preventative medicine is heading.
PlayPowerfulJREJoe Rogan Experience #2376 — Brigham BuhlerBrigham Buhler, founder of Ways2WellA former pharmaceutical sales insider on how the industry is structured, why certain compounds are hard to access, and the compounding pharmacy landscape.
PlayPowerfulJREJoe Rogan Experience #2079 — Brigham BuhlerBrigham Buhler, founder of Ways2WellThe first of the series. Diagnostics, hormone testing, compounded peptides and stem cell therapy, and the regulatory friction around each.
PlayAlbert and Mary Lasker FoundationFighting Obesity: The GLP-1 RevolutionJoel Habener, Svetlana Mojsov and Lotte Bjerre KnudsenThe Lasker Foundation's citation film traces how a fragment of the proglucagon gene product was identified as glucagon-like peptide-1 and how that laboratory finding was later engineered into a class of medicines.
PlayNobel Prize2012 Nobel Lectures in ChemistryRobert Lefkowitz and Brian KobilkaThe two laureates deliver their Nobel lectures on G protein-coupled receptors: how the receptors were first identified biochemically, how they were cloned, and how their activated structure was finally solved.
PlayCanadaGairdnerAwardsDr. Daniel Drucker Gairdner Science Week Laureate LectureDaniel DruckerDrucker sets out the biology of the proglucagon-derived peptides, the receptors they act on, and how basic endocrinology work over four decades was translated into pharmacology.
PlayUC Riverside School of MedicineJens Juul Holst, MD: 2024 UCR SOM Haider Biomedical Breakthrough LectureJens Juul HolstA co-discoverer of GLP-1 gives a full academic lecture on gut hormone physiology, the incretin effect, and how the peptide's very short half-life in the body shaped later drug design.
PlayiBiology Science StoriesJeffrey Friedman (Rockefeller U./HHMI): The Causes of Obesity and the Discovery of LeptinJeffrey FriedmanFriedman recounts the positional cloning of the ob gene and the identification of leptin, a peptide hormone secreted by fat tissue that signals energy stores to the brain.
PlayNOVA PBS OfficialOzempic Quiets Your Appetite Using Your Brain | NOVA | PBSNOVA (PBS) science unitA public-service explainer on why researchers now think GLP-1 receptor agonists act substantially in the brain rather than mainly in the gut, and what remains unresolved about that mechanism.
PlayThe National Academies of Sciences, Engineering, and MedicineDiscover the Science and Impact of GLP-1 Weight Loss Drugs | Webinar RecapNational Academies expert panelA convened panel of researchers discusses how GLP-1 receptor agonists work, what the long-term evidence base does and does not yet cover, and the societal questions raised by their rapid uptake.
PlayNobel PrizeNobel Prize lecture: David Baker, Nobel Prize in Chemistry 2024David BakerBaker's Nobel lecture on computational protein design, including how short designed peptides and miniproteins can be built to bind chosen targets.
PlayCambridge FestivalIn a post-Ozempic world, have we cured obesity? Professor Giles YeoGiles YeoA Cambridge geneticist explains the mechanism of action of GLP-1 receptor agonists and then argues carefully about what these drugs do and do not resolve at a population level.The library
Everything, by subject.
PlayStart Here · 2026Joe Rogan Experience #2469 — Brigham BuhlerBrigham Buhler, founder of Ways2WellThe most recent of the Ways2Well conversations. Covers the healthcare system, the regulatory position around peptides and hormones, and where Buhler argues preventative medicine is heading.PlayStart Here · 2025Joe Rogan Experience #2376 — Brigham BuhlerBrigham Buhler, founder of Ways2WellA former pharmaceutical sales insider on how the industry is structured, why certain compounds are hard to access, and the compounding pharmacy landscape.PlayStart Here · 2024Joe Rogan Experience #2079 — Brigham BuhlerBrigham Buhler, founder of Ways2WellThe first of the series. Diagnostics, hormone testing, compounded peptides and stem cell therapy, and the regulatory friction around each.
PlayPeptides ExplainedThe Emerging Science and Clinical Application of Peptide TherapyNorthwestern Univ. Feinberg School of MedicineA medical school lecture on peptide therapeutics — what the class is, how these molecules are used clinically, and where the research currently sits.
PlayPeptides ExplainedMetabolic Hormone Signaling and PhysiologyBethany Cummings, DVM, PhDHow GLP-1 and related gut hormones signal, from a university discovery forum. The clearest available explanation of the incretin biology behind the metabolic compound class.
PlayPeptides ExplainedOrigins & Effects of BPC-157Dr. Abud Bakri & Dr. Andrew HubermanWhere BPC-157 was identified, what the preclinical literature investigates, and how the molecule is described mechanistically. Pair it with the surgeon’s response under Safety.
PlayPeptides ExplainedWhat are peptides and why is the FDA considering easing limits?NBC NewsA short news explainer on the compound class and the regulatory reclassification question, for anyone starting from zero.
PlayLongevity & healthy ageingLongevity: Separating the Science From the FictionMatt Kaeberlein, PhDA biogerontologist on which longevity claims have evidence behind them and which do not. The best single starting point in this section.
PlayLongevity & healthy ageingAn Introduction to the Biology of AgingMatt Kaeberlein, PhDA full academic primer on ageing biology, delivered to a research society rather than a general audience.
PlayLongevity & healthy ageingTargeting biological ageing: a new paradigm for 21st century medicineMatt Kaeberlein, PhDThe case for treating ageing biology as a therapeutic target, presented at a university medical faculty.
PlayLongevity & healthy ageingLongevity science: from molecules to pets to clinical practiceMatt Kaeberlein, PhDHow findings move from model organisms through companion-animal studies toward clinical work — and how much is lost at each step.
PlayLongevity & healthy ageingFrom Dogs to Humans: Translational Aging InsightsMatt Kaeberlein, PhDOn the Dog Aging Project and what companion-animal research can and cannot tell us about human ageing.
PlayLongevity & healthy ageingCan We Slow Aging? The Real Science Behind LongevityMatt Kaeberlein, PhDA general-audience version of the same argument, useful if the academic lectures are heavier than you want.
PlayPerformance & recoveryPerformance-enhancing drugs and hormones — risks, rewards, and implicationsPeter Attia MDA long, unusually candid discussion of performance pharmacology that spends as much time on risk as on effect.
PlayPerformance & recoveryThe Healing Peptides: BPC-157 & GHK-CuCo-Movement GymA practitioner walkthrough of the two compounds most discussed in tissue-repair research, and what the studies actually examined.
PlayPerformance & recoveryDr. Attia on the dumbest health trendsPeter Attia, MDAttia on which popular interventions he considers unsupported. Included as a corrective — the point of this library is not that everything works.
PlayExpert interviewsLongevity Scientist: Fasting, Supplements & Tools for Ageing WellMatt Kaeberlein, PhDA long interview covering fasting, supplements and what a researcher does and does not personally find convincing.
PlayExpert interviewsTop Doctors Tackle Huberman’s Claims on BPC-157 and CancerDr. Melissa PetersenClinicians examining a widely shared claim about BPC-157 and cancer risk. A direct example of a popular assertion being interrogated.
PlayScience & researchHow nutrition impacts longevityMatt Kaeberlein, PhDTwo researchers working through the nutrition and longevity literature, including where the human evidence thins out.
PlayScience & researchUnderstanding Aging & Disease and How They’re RelatedMatt Kaeberlein, PhDWhy age is the dominant risk factor for most chronic disease, and what follows from treating it as one.
PlaySafety, quality & responsible useSurgeon on the peptides Joe Rogan injects — and the missing human safety dataDr. Chris Raynor | Not Your Everyday OrthoAn orthopaedic surgeon reviewing the evidence base behind widely discussed peptides, and where human safety data does not exist. Watch this alongside the BPC-157 explainer.
PlaySafety, quality & responsible useHealth officials caution against unapproved peptide productsCBS TEXASRegulators and clinicians on unapproved products sold online, and why "research use only" labelling is not a safety assurance.
PlaySafety, quality & responsible useDoctor breaks down peptide safetyCBS NewsA short broadcast segment on what is known and unknown about safety.
PlaySafety, quality & responsible useUnderstanding the Impact of FDA Regulations on Injectable PeptidesDrew Timmermans, ND, RMSKHow the compounding categories work and what reclassification changes in practice.
PlaySafety, quality & responsible useThe FDA reclassified 12 peptides — a clinician on which he would still avoidDr. Abs MChD BChD BSc FRSM FRSPH CISSN MISCTA clinician working through the reclassified list compound by compound and explaining where he thinks the evidence remains too thin.PlayStart HereFighting Obesity: The GLP-1 RevolutionJoel Habener, Svetlana Mojsov and Lotte Bjerre KnudsenThe Lasker Foundation's citation film traces how a fragment of the proglucagon gene product was identified as glucagon-like peptide-1 and how that laboratory finding was later engineered into a class of medicines.PlayStart Here2012 Nobel Lectures in ChemistryRobert Lefkowitz and Brian KobilkaThe two laureates deliver their Nobel lectures on G protein-coupled receptors: how the receptors were first identified biochemically, how they were cloned, and how their activated structure was finally solved.PlayStart HereDr. Daniel Drucker Gairdner Science Week Laureate LectureDaniel DruckerDrucker sets out the biology of the proglucagon-derived peptides, the receptors they act on, and how basic endocrinology work over four decades was translated into pharmacology.PlayStart HereJens Juul Holst, MD: 2024 UCR SOM Haider Biomedical Breakthrough LectureJens Juul HolstA co-discoverer of GLP-1 gives a full academic lecture on gut hormone physiology, the incretin effect, and how the peptide's very short half-life in the body shaped later drug design.PlayStart HereJeffrey Friedman (Rockefeller U./HHMI): The Causes of Obesity and the Discovery of LeptinJeffrey FriedmanFriedman recounts the positional cloning of the ob gene and the identification of leptin, a peptide hormone secreted by fat tissue that signals energy stores to the brain.PlayStart HereOzempic Quiets Your Appetite Using Your Brain | NOVA | PBSNOVA (PBS) science unitA public-service explainer on why researchers now think GLP-1 receptor agonists act substantially in the brain rather than mainly in the gut, and what remains unresolved about that mechanism.PlayStart HereDiscover the Science and Impact of GLP-1 Weight Loss Drugs | Webinar RecapNational Academies expert panelA convened panel of researchers discusses how GLP-1 receptor agonists work, what the long-term evidence base does and does not yet cover, and the societal questions raised by their rapid uptake.PlayStart HereNobel Prize lecture: David Baker, Nobel Prize in Chemistry 2024David BakerBaker's Nobel lecture on computational protein design, including how short designed peptides and miniproteins can be built to bind chosen targets.PlayStart HereIn a post-Ozempic world, have we cured obesity? Professor Giles YeoGiles YeoA Cambridge geneticist explains the mechanism of action of GLP-1 receptor agonists and then argues carefully about what these drugs do and do not resolve at a population level.
PlayPeptides Explained3. Structures of Amino Acids, Peptides, and ProteinsBarbara ImperialiAn MIT introductory biology lecture covering amino acid chemistry, how the peptide bond forms and why it is planar, and how chains of amino acids fold into functional structures.
PlayPeptides ExplainedGrand Rounds- Mechanism of Action of Protein and Peptide HormonesMario AscoliA grand rounds lecture on how protein and peptide hormones are synthesised, processed from precursors, released, and how they signal through cell-surface receptors and second messengers.
PlayPeptides ExplainedReceptor Basics - Robert Lefkowitz (Duke University)Robert LefkowitzLefkowitz explains the basic concept of a receptor, how binding was first measured experimentally, and why receptor number and affinity govern what a signalling molecule can do.
PlayPeptides ExplainedUnit 6 Part 6 Bruce Merrifield and Peptide SynthesisBruce Merrifield (presented by Kyoto University)A short university course segment on solid-phase peptide synthesis, the method Merrifield invented for building a peptide chain step by step on a solid support.
PlayPeptides ExplainedLecture 27: Peptide coupling agents, Solid phase synthesis, peptide based therapeuticsLal Mohan KunduA chemistry lecture on the coupling reagents and protecting-group strategy used to join amino acids, and on the properties that make peptides attractive but difficult as drug molecules.
PlayPeptides ExplainedRandy Schekman (HHMI & UCB) 1: Secretory Pathway: How cells package & traffic proteins for exportRandy SchekmanSchekman describes how cells manufacture proteins and peptides and then package and traffic them for release, the pathway his Nobel-recognised genetic screens uncovered.
PlayPeptides Explained8. Protein Folding 1Elizabeth NolanAn MIT biological chemistry lecture on how the ribosome assembles amino acids into a chain and on the principles that determine how that chain then folds.
PlayScience & researchTranslational Biology of the Glucagon-like Peptides in Metabolic MedicineDaniel DruckerAn endocrinology grand rounds in which Drucker works through the biology of the glucagon-like peptides, their receptor distribution across tissues, and the mechanistic questions the field has not yet answered.
PlayScience & researchPhysiology 2021: Michael de Burgh Daly Prize LectureFiona GribbleGribble's prize lecture on the gut endocrine axis: the scattered enteroendocrine cells of the intestinal lining, the hormones they secrete, and how those signals reach the brain and pancreas.
PlayScience & researchEnterochromaffin cells, endocrine cells and brush border cells by Fiona GribbleFiona GribbleA specialist talk on the distinct sensory cell types of the gut lining and the different peptide and amine signals each one releases.
PlayScience & researchKeynote Lecture - Professor Brian KobilkaBrian KobilkaKobilka's keynote on the structural biology of G protein-coupled receptors and the difficulty of capturing a receptor in its active state for drug discovery.
PlayScience & researchJeffrey Friedman: Keynote LectureJeffrey FriedmanFriedman presents current work on leptin signalling and the neural circuits through which a peripheral peptide hormone influences feeding behaviour.
PlayScience & researchICE/ECE 2012, Plenary Lecture 7, Professor NauckMichael NauckNauck's plenary on the incretin effect: the observation that oral glucose provokes a far larger insulin response than intravenous glucose, and the gut peptides responsible for that difference.
PlayScience & researchHot Topics: Matthias TschoepMatthias TschöpTschöp discusses unimolecular multi-agonist design, in which a single engineered peptide is built to act at more than one gut hormone receptor at once.
PlayScience & researchWhat bariatric surgery tells us about the role of the gut in metabolism | Professor Randy SeeleyRandy SeeleySeeley uses bariatric surgery as an experimental probe, arguing from animal and human data that rearranging the gut changes metabolic regulation through altered gut signalling rather than restriction alone.
PlayScience & researchRothman and Schekman: Uncovering the Secretory PathwayJames Rothman and Randy SchekmanTwo Nobel laureates recount the parallel genetic and biochemical work that revealed how vesicles carry proteins and peptide hormones through the cell and release them at the surface.
PlayScience & researchImmunology Fall 2019 Lecture 3: Antimicrobial Peptides and ComplementBrianne BarkerA university immunology lecture on antimicrobial peptides, a wholly separate class of short peptides that the body produces as part of innate defence.
PlayLongevity & healthy ageingDena Dubal - ‘X’ Marks the Spot in Female Longevity and Cognitive Aging (April 28, 2021)Dena DubalDubal presents laboratory work on sex chromosome contributions to lifespan and on klotho, a protein whose circulating fragment she studies in relation to cognitive ageing.
PlayLongevity & healthy ageingDr. Dena Dubal discusses "Longevity Factor Klotho, Aging, and Neurodegenerative Disease"Dena DubalA short institutional introduction in which Dubal outlines what klotho is, how variants in its gene were associated with cognition, and what her laboratory is testing next.
PlayLongevity & healthy ageingLongevity Genes (1 of 5): Nir Barzilai, M.D.Nir BarzilaiBarzilai describes the Longevity Genes Project and the hormonal and genetic differences observed in families with exceptional lifespans, including altered growth hormone and IGF-1 signalling.
PlayLongevity & healthy ageingIs There A Longevity Gene? The Biology of Aging with Nir Barzilai, MDNir BarzilaiA public lecture on the biology of ageing, centenarian genetics, and why Barzilai argues that ageing itself rather than individual diseases should be the research target.
PlayLongevity & healthy ageingUSC Longevity Scientist Dr. Valter Longo: Why Growth Hormone Peptides Age You FasterValter LongoLongo sets out the evidence from growth hormone receptor deficiency in humans and from animal models, and argues that raising growth hormone and IGF-1 signalling runs against what the longevity data show.
PlayLongevity & healthy ageingNatalie Ebner - Oxytocin and human agingNatalie EbnerEbner reviews research on the neuropeptide oxytocin across the adult lifespan, including how the findings are complicated by measurement problems and inconsistent results.
PlayLongevity & healthy ageingGreg Fahy | Thymus Regeneration: What’s Next? @ Longevity Frontiers Workshop 2023Greg FahyFahy describes his small clinical studies on thymus regeneration, the biomarker changes reported, and the substantial limitations of trials run at that scale.
PlayLongevity & healthy ageingGLP-1s and Aging: Risks, Benefits & Weight Loss After 60 | Mayo Clinic Aging Forward PodcastAndres Acosta and Christina ChenTwo Mayo Clinic physicians discuss what is known about GLP-1 receptor agonists in older adults, including reported concerns around loss of muscle mass, frailty and nutrition.
PlayPerformance & recoveryThe Effects of Growth Hormone on Athletic PerformanceAnnals of Internal Medicine (systematic review authors)A journal summary of a systematic review of growth hormone use in healthy older adults, reporting that the measured benefits were small and that adverse effects were common.
PlayPerformance & recoveryHGH Improves Athletic PerformanceAnnals of Internal Medicine (trial authors)A journal summary of a controlled trial in recreational athletes reporting an increase in sprint capacity with growth hormone, with no measured gain in strength, power or endurance.
PlayPerformance & recoverySENS5 - Myostatin: Modulator of Muscle Mass, Mobility and MetabolismNathan LeBrasseurA Mayo Clinic researcher presents work on myostatin, a secreted protein that acts as a brake on skeletal muscle growth, and on what happens metabolically when that brake is released in animal models.
PlayPerformance & recoveryOptimizing Your Health: Q&A with Professor Keith Baar on Exercise, Collagen, and RecoveryKeith BaarBaar answers questions on tendon and ligament biology, on how mechanical loading drives collagen synthesis, and on what his laboratory's collagen and gelatin studies did and did not show.
PlayPerformance & recoveryKeith Baar - Physical training, performance and injury preventionKeith BaarA sports science congress keynote on how muscle and connective tissue adapt to loading, and on the molecular signalling that determines whether tissue strengthens or fails.
PlayPerformance & recoveryManipulating muscle protein turnover to maximize exercise adaptations, Stuart PhillipsStuart PhillipsPhillips presents the physiology of muscle protein synthesis and breakdown, and how training and amino acid availability shift the balance between them.
PlayPerformance & recoveryThe Science of Doping: Revving Up Blood to Improve PerformanceWall Street Journal science deskA short explainer on blood doping and erythropoietin, a peptide hormone that regulates red blood cell production, and on how anti-doping authorities try to detect its misuse.
PlayExpert interviewsLife in the Balance: Lotte Bjerre Knudsen and Jens Juul Holst Tell the GLP-1 StoryLotte Bjerre Knudsen and Jens Juul HolstA discoverer and a protein engineer describe, in their own words, the decades between identifying a gut peptide and turning it into a stable molecule.
PlayExpert interviewsThe Discovery of Glucagon-Like Peptide 1 (GLP-1)Svetlana MojsovA JAMA senior editor interviews Mojsov, the peptide chemist who determined the biologically active form of GLP-1, about the experiments and about how her contribution was recorded.
PlayExpert interviewsSamuel Klein on GLP-1 Revolution, Metabolism, and the Future of Obesity MedicineSamuel KleinA metabolism researcher discusses insulin resistance, the biology of obesity, and how he reads the evidence around GLP-1 medicines against decades of earlier work.
PlayExpert interviewsDr. Ania Jastreboff: The Revolution in Obesity MedicationAnia JastreboffJastreboff explains obesity as a disease of energy regulation and discusses how the newer incretin-based medicines were tested and what the trial endpoints actually measured.
PlayExpert interviewsAnia Jastreboff: The Transformative Obesity DrugsAnia JastreboffA longer conversation on the biology these drugs engage, on discontinuation and weight regain, and on the access and cost questions their success created.
PlayExpert interviewsMedical Interventions to Treat Obesity: How They Work (feat. Dr. Randy Seeley)Randy SeeleySeeley explains for a non-specialist audience how the brain defends body weight and where pharmacological and surgical interventions act on that system.
PlaySafety, quality & responsible useFDA panel votes to ease restrictions on an unregulated peptide BPC-157NBC News correspondentsA news report on the FDA advisory committee vote concerning BPC-157 and what an advisory recommendation does and does not mean in regulatory terms.
PlaySafety, quality & responsible useFDA Drug Topics - Regulatory Framework for Human Drug CompoundingU.S. Food and Drug Administration staffThe FDA's own educational session on how drug compounding is regulated, covering the distinction between 503A and 503B facilities and where compounded products sit relative to approved drugs.
PlaySafety, quality & responsible useFDA will review compound peptides and whether to allow pharmacies to make themNBC Chicago news teamA local news report setting out what the FDA review of compounded peptides covers and why the agency has flagged safety concerns about unapproved products.
PlaySafety, quality & responsible useFDA warns consumers of counterfeit versions of weight loss drug OzempicNBC News health deskA report on FDA seizures of counterfeit semaglutide products, including counterfeit packaging and needles entering the legitimate supply chain.
PlaySafety, quality & responsible use‘I almost died from a fake weight loss injection’Channel 4 News investigations teamAn investigation into fake weight-loss injections sold online, following a case in which a person was hospitalised after using an illegitimate product.
PlaySafety, quality & responsible useThe Truth About The 'Skinny' Jab | Channel 4 DocumentariesChannel 4 documentary teamA documentary examining how weight-loss injections are being obtained and sold in the UK, including through channels operating outside proper medical oversight.
PlaySafety, quality & responsible useWhat Happens When You Stop ‘Skinny Jabs’? | BBC NewsBBC News health teamA BBC report on what published follow-up data show about weight regain after these medicines are discontinued.
PlaySafety, quality & responsible useWhat possible compounded semaglutide ban means for patientsCBS News medical correspondentA broadcast explainer on the end of the compounding exemption once the FDA declared the shortage resolved, and what that change meant legally.
PlaySafety, quality & responsible usePeople with healthy BMI using AI to get weight-loss jabs, ITV News finds | Good Morning BritainITV News investigations teamAn investigation finding that people with a healthy BMI obtained prescriptions from online pharmacies by submitting digitally altered photographs.
PlaySafety, quality & responsible usePeptide BPC-157 - Does It Work? Breaking Down the Evidence and the HypeBrad Weening and Paul ZieglerTwo orthopaedic surgeons work through the published BPC-157 literature and point out that it is overwhelmingly preclinical, with essentially no controlled human evidence behind the claims made for it.The counts on this site come from the published record, not from a film. Read the citation index — including the compound classes where the trial count is zero.
82 films · 7 subjects